RT Journal Article SR Electronic T1 Sex differences in the decline of neutralizing antibodies to SARS-CoV-2 JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.11.12.20230466 DO 10.1101/2020.11.12.20230466 A1 Ludivine Grzelak A1 Aurélie Velay A1 Yoann Madec A1 Floriane Gallais A1 Isabelle Staropoli A1 Catherine Schmidt-Mutter A1 Marie-Josée Wendling A1 Nicolas Meyer A1 Cyril Planchais A1 David Rey A1 Hugo Mouquet A1 Ludovic Glady A1 Yves Hansmann A1 Timothée Bruel A1 Jérome De Sèze A1 Arnaud Fontanet A1 Maria Gonzalez A1 Olivier Schwartz A1 Samira Fafi-Kremer YR 2020 UL http://medrxiv.org/content/early/2020/11/15/2020.11.12.20230466.abstract AB The evolution of SARS-CoV-2 humoral response in infected individuals remains poorly characterized. Here, we performed a longitudinal study of sera from 308 RT-qPCR+ individuals with mild disease, collected at two time-points, up to 6 months post-onset of symptoms (POS). We performed two anti-S and one anti-N serology assays and quantified neutralizing antibodies (NAbs). At month 1 (M1), males, individuals > 50 years of age or with a body mass index (BMI) > 25 exhibited higher levels of antibodies. Antibody levels decreased over time. At M3-6, anti-S antibodies persisted in 99% of individuals while anti-N IgG were measurable in only 59% of individuals. The decline in anti-S and NAbs was faster in males than in females, independently of age and BMI. Our results show that some serology tests are less reliable overtime and suggest that the duration of protection after SARS-CoV-2 infection or vaccination will be different in women and men.Competing Interest StatementSFK, YM, RG, LT, FA, PS, CSM, NC, AB, AV, NL, MM, NM, DR, BH, JDS and AF have no competing interest to declare. LG, IS, TB, and OS are holder of a provisional patent on the S-Flow assayClinical TrialNCT04441684Clinical Protocols https://clinicaltrials.gov/ct2/show/study/NCT04441684 Funding StatementSFK lab is funded by Strasbourg University Hospitals (SeroCoV-HUS; PRI 7782), the Agence Nationale de la Recherche (ANR-18-CE17-0028), Laboratoire d'Excellence TRANSPLANTEX (ANR-11-LABX-0070_TRANSPLANTEX), and Institut National de la Sante et de la Recherche Medicale (UMR_S 1109). O.S. is funded by Institut Pasteur, Urgence COVID-19 Fundraising Campaign of Institut Pasteur, ANRS, Sidaction, the Vaccine Research Institute (ANR-10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), "TIMTAMDEN" ANR-14-CE14-0029, "CHIKV-Viro-Immuno" ANR-14-CE14-0015-01, and the Gilead HIV cure program. ANR/Fondation Pour la Recherche Medicale Flash COVID. LG is supported by the French Ministry of Higher Education, Research and Innovation. The funders had no role in study design, data collection, interpretation, or the decision to submit the work for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study has been approved by the CPP (comite de protection des personnes) SUD MEDITERRANEE III, Number 2020.04.15 bis_ 20.04.10.66856 and has been registered at ClinicalTrials.gov under the identifier: NCT04441684All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available